Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
1(100.0%)
1Total
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01372670Phase 4Withdrawn

Does Hydroxyzine Decrease Anxiety in Underweight Patients Diagnosed With an Eating Disorder

Role: collaborator

NCT00948311Completed

Develop and Validate a Self-Administered Instrument That Will Screen for Eating Disorder Symptoms in Persons Aged 12 and Older With Type 1 Diabetes.

Role: collaborator

NCT00818142Completed

Support Group Surveys for Individuals Who Have Type 1 Diabetes and an Eating Disorder

Role: collaborator

NCT00945711Completed

Characteristics of Persons With an Eating Disorder and Type 1 Diabetes

Role: collaborator

All 4 trials loaded